The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Respiratory Syncytial Virus (RSV) Diagnostics Market Research Report 2025
Synopsis
The global Respiratory Syncytial Virus (RSV) Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Syncytial Virus (RSV) Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Syncytial Virus (RSV) Diagnostics.
Report Scope
The Respiratory Syncytial Virus (RSV) Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Respiratory Syncytial Virus (RSV) Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Syncytial Virus (RSV) Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
AstraZeneca
Merck
AbbVie
Bausch Health
GlaxoSmithKline
ReViral
Gilead Sciences
Teva Pharmaceutical
Segment by Type
Molecular Diagnosis
Rapid Antigen Testing
Other
Segment by Application
Hospital
Clinic
Laborary
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus (RSV) Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Respiratory Syncytial Virus (RSV) Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Syncytial Virus (RSV) Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Syncytial Virus (RSV) Diagnostics.
Report Scope
The Respiratory Syncytial Virus (RSV) Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Respiratory Syncytial Virus (RSV) Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Syncytial Virus (RSV) Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
AstraZeneca
Merck
AbbVie
Bausch Health
GlaxoSmithKline
ReViral
Gilead Sciences
Teva Pharmaceutical
Segment by Type
Molecular Diagnosis
Rapid Antigen Testing
Other
Segment by Application
Hospital
Clinic
Laborary
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus (RSV) Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Molecular Diagnosis
1.2.3 Rapid Antigen Testing
1.2.4 Other
1.3 Market by Application
1.3.1 Global Respiratory Syncytial Virus (RSV) Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Laborary
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Syncytial Virus (RSV) Diagnostics Market Perspective (2019-2030)
2.2 Respiratory Syncytial Virus (RSV) Diagnostics Growth Trends by Region
2.2.1 Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Respiratory Syncytial Virus (RSV) Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Respiratory Syncytial Virus (RSV) Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Respiratory Syncytial Virus (RSV) Diagnostics Market Dynamics
2.3.1 Respiratory Syncytial Virus (RSV) Diagnostics Industry Trends
2.3.2 Respiratory Syncytial Virus (RSV) Diagnostics Market Drivers
2.3.3 Respiratory Syncytial Virus (RSV) Diagnostics Market Challenges
2.3.4 Respiratory Syncytial Virus (RSV) Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Syncytial Virus (RSV) Diagnostics Players by Revenue
3.1.1 Global Top Respiratory Syncytial Virus (RSV) Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Respiratory Syncytial Virus (RSV) Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Respiratory Syncytial Virus (RSV) Diagnostics Revenue
3.4 Global Respiratory Syncytial Virus (RSV) Diagnostics Market Concentration Ratio
3.4.1 Global Respiratory Syncytial Virus (RSV) Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Syncytial Virus (RSV) Diagnostics Revenue in 2023
3.5 Respiratory Syncytial Virus (RSV) Diagnostics Key Players Head office and Area Served
3.6 Key Players Respiratory Syncytial Virus (RSV) Diagnostics Product Solution and Service
3.7 Date of Enter into Respiratory Syncytial Virus (RSV) Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Syncytial Virus (RSV) Diagnostics Breakdown Data by Type
4.1 Global Respiratory Syncytial Virus (RSV) Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Respiratory Syncytial Virus (RSV) Diagnostics Forecasted Market Size by Type (2025-2030)
5 Respiratory Syncytial Virus (RSV) Diagnostics Breakdown Data by Application
5.1 Global Respiratory Syncytial Virus (RSV) Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Respiratory Syncytial Virus (RSV) Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Respiratory Syncytial Virus (RSV) Diagnostics Market Size (2019-2030)
6.2 North America Respiratory Syncytial Virus (RSV) Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2019-2024)
6.4 North America Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Size (2019-2030)
7.2 Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2019-2024)
7.4 Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Size (2019-2030)
9.2 Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.1.4 Roche Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.1.5 Roche Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.2.4 AstraZeneca Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.2.5 AstraZeneca Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.3.4 Merck Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.3.5 Merck Recent Development
11.4 AbbVie
11.4.1 AbbVie Company Detail
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.4.4 AbbVie Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.4.5 AbbVie Recent Development
11.5 Bausch Health
11.5.1 Bausch Health Company Detail
11.5.2 Bausch Health Business Overview
11.5.3 Bausch Health Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.5.4 Bausch Health Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.5.5 Bausch Health Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.6.4 GlaxoSmithKline Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.6.5 GlaxoSmithKline Recent Development
11.7 ReViral
11.7.1 ReViral Company Detail
11.7.2 ReViral Business Overview
11.7.3 ReViral Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.7.4 ReViral Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.7.5 ReViral Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Detail
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.8.4 Gilead Sciences Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.8.5 Gilead Sciences Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Detail
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Respiratory Syncytial Virus (RSV) Diagnostics Introduction
11.9.4 Teva Pharmaceutical Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
11.9.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Molecular Diagnosis
Table 3. Key Players of Rapid Antigen Testing
Table 4. Key Players of Other
Table 5. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Region (2019-2024)
Table 9. Global Respiratory Syncytial Virus (RSV) Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Region (2025-2030)
Table 11. Respiratory Syncytial Virus (RSV) Diagnostics Market Trends
Table 12. Respiratory Syncytial Virus (RSV) Diagnostics Market Drivers
Table 13. Respiratory Syncytial Virus (RSV) Diagnostics Market Challenges
Table 14. Respiratory Syncytial Virus (RSV) Diagnostics Market Restraints
Table 15. Global Respiratory Syncytial Virus (RSV) Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Players (2019-2024)
Table 17. Global Top Respiratory Syncytial Virus (RSV) Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus (RSV) Diagnostics as of 2023)
Table 18. Ranking of Global Top Respiratory Syncytial Virus (RSV) Diagnostics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Respiratory Syncytial Virus (RSV) Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Respiratory Syncytial Virus (RSV) Diagnostics Product Solution and Service
Table 22. Date of Enter into Respiratory Syncytial Virus (RSV) Diagnostics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Respiratory Syncytial Virus (RSV) Diagnostics Revenue Market Share by Type (2019-2024)
Table 26. Global Respiratory Syncytial Virus (RSV) Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Respiratory Syncytial Virus (RSV) Diagnostics Revenue Market Share by Type (2025-2030)
Table 28. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Respiratory Syncytial Virus (RSV) Diagnostics Revenue Market Share by Application (2019-2024)
Table 30. Global Respiratory Syncytial Virus (RSV) Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Respiratory Syncytial Virus (RSV) Diagnostics Revenue Market Share by Application (2025-2030)
Table 32. North America Respiratory Syncytial Virus (RSV) Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Roche Company Detail
Table 48. Roche Business Overview
Table 49. Roche Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 50. Roche Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 51. Roche Recent Development
Table 52. AstraZeneca Company Detail
Table 53. AstraZeneca Business Overview
Table 54. AstraZeneca Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 55. AstraZeneca Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 56. AstraZeneca Recent Development
Table 57. Merck Company Detail
Table 58. Merck Business Overview
Table 59. Merck Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 60. Merck Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 61. Merck Recent Development
Table 62. AbbVie Company Detail
Table 63. AbbVie Business Overview
Table 64. AbbVie Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 65. AbbVie Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 66. AbbVie Recent Development
Table 67. Bausch Health Company Detail
Table 68. Bausch Health Business Overview
Table 69. Bausch Health Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 70. Bausch Health Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 71. Bausch Health Recent Development
Table 72. GlaxoSmithKline Company Detail
Table 73. GlaxoSmithKline Business Overview
Table 74. GlaxoSmithKline Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 75. GlaxoSmithKline Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 76. GlaxoSmithKline Recent Development
Table 77. ReViral Company Detail
Table 78. ReViral Business Overview
Table 79. ReViral Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 80. ReViral Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 81. ReViral Recent Development
Table 82. Gilead Sciences Company Detail
Table 83. Gilead Sciences Business Overview
Table 84. Gilead Sciences Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 85. Gilead Sciences Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 86. Gilead Sciences Recent Development
Table 87. Teva Pharmaceutical Company Detail
Table 88. Teva Pharmaceutical Business Overview
Table 89. Teva Pharmaceutical Respiratory Syncytial Virus (RSV) Diagnostics Product
Table 90. Teva Pharmaceutical Revenue in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024) & (US$ Million)
Table 91. Teva Pharmaceutical Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. Molecular Diagnosis Features
Figure 4. Rapid Antigen Testing Features
Figure 5. Other Features
Figure 6. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Application: 2023 VS 2030
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Laborary Case Studies
Figure 11. Other Case Studies
Figure 12. Respiratory Syncytial Virus (RSV) Diagnostics Report Years Considered
Figure 13. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Region: 2023 VS 2030
Figure 16. Global Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Players in 2023
Figure 17. Global Top Respiratory Syncytial Virus (RSV) Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus (RSV) Diagnostics as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Respiratory Syncytial Virus (RSV) Diagnostics Revenue in 2023
Figure 19. North America Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Country (2019-2030)
Figure 21. United States Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Country (2019-2030)
Figure 25. Germany Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Region (2019-2030)
Figure 33. China Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Country (2019-2030)
Figure 41. Mexico Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Respiratory Syncytial Virus (RSV) Diagnostics Market Share by Country (2019-2030)
Figure 45. Turkey Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Respiratory Syncytial Virus (RSV) Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Roche Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 48. AstraZeneca Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 49. Merck Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 50. AbbVie Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 51. Bausch Health Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 52. GlaxoSmithKline Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 53. ReViral Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 54. Gilead Sciences Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 55. Teva Pharmaceutical Revenue Growth Rate in Respiratory Syncytial Virus (RSV) Diagnostics Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
